A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers

Trial Profile

A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Napabucasin (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 11 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 03 Sep 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 17 Jul 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top